Neurotransmitter and intracellular mechanisms of bipolar disorder; an explanation of Kato's theory of mood-stabilising neurons

Author/s
James Edmonds, Mark Agius
Citation
Issue 3 Summer 2013
CEPiP.2013;1:123-130
Abstract

Investigations into the neurobiology of bipolar disorder have produced evidence of abnormalities within many processes and chemicals in the brain. There are differences between bipolar disorder patients and controls in terms of the functioning of neurotransmitters such as dopamine, intracellular messengers such as GSK-3b, protein kinase C and calcium, and organelles such as mitochondria and the endoplasmic reticulum. A large number of genes have been identified as increasing the risk of bipolar disorder. This article reviews this evidence and examines the hypothesis that these observed abnormalities are contributing towards, or resulting from, a fundamental neurodegenerative process which affects neurons which ordinarily have a ‘mood stabilising’ effect.

Keywords: bipolar disorder, neurobiology, dopamine, calcium, mood stabilisers, neurodegeneration

Cite as: Cutting Edge Psychiatry in Practice 2013, 3(1):123-130; https://doi.org/10.65031/kfeq2558

References

  1. Kato T. Molecular neurobiology of bipolar disorder: a disease of ‘mood-stabilizing neurons’? Trends Neurosci. 2008 Oct;31 (10):495-503. https://doi.org/10.1016/j.tins.2008.07.007
  2. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br. J. Psychiatry 1994;164:549–550. https://doi.org/10.1192/bjp.164.4.549
  3. Valentini V et al. Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine. J.Neurochem. 2004;88:917–927. https://doi.org/10.1046/j.1471-4159.2003.02238.x
  4. Zhou QY, Palmiter RD. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 1995;83:1197–1209. https://doi.org/10.1016/0092-8674(95)90145-0
  5. Nishii K et al. Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission. J. Neurosci. Res. 1998;54:450–464. https://doi.org/10.1002/(sici)1097-4547(19981115)54:4<450::aid-jnr3>3.0.co;2-b
  6. Torack RM, Morris, JC. The association of ventral tegmental area histopathology with adult dementia. Arch. Neurol. 1988;’45:497–501. https://doi.org/10.1001/archneur.1988.00520290025008
  7. Goodwin FK, Jamison KR. Manic-Depressive Illness. 2nd edn. Oxford University Press; 2007.
  8. Mahmood T, Silverstone T. Serotonin and bipolar disorder. J. Affect. Disord. 2001;66:1–11.                
  9. Kato T. Role of mitochondrial DNA in calcium signalling abnormality in bipolar disorder. Cell Calcium 2008;44:92–102. https://doi.org/10.1016/j.ceca.2007.11.005
  10. Warsh JJ et al. Role of intracellular calcium signaling in the pathophysiology and pharmacotherapy of bipolar disorder: current status. Clin.Neurosci. Res. 2004;4:201–213. https://doi.org/10.1016/j.cnr.2004.09.012
  11. Hough C et al. Elevated basal and thapsigargin-stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay. Biol. Psychiatry 1999;46:247–255. https://doi.org/10.1016/s0006-3223(98)00308-4
  12. Kato T et al. Mechanisms of altered Ca2+ signalling in transformed lymphoblastoid cells from patients with bipolar disorder. Int. J. Neuropsychopharmacol. 2003;6:379–389. https://doi.org/10.1017/s1461145703003717
  13. Belmaker RH et al. Reduced inositol content in lymphocyte derived cell lines from bipolar patients. Bipolar Disord. 2002;4:67–69. https://doi.org/10.1034/j.1399-5618.2002.00108.x
  14. Nemanov L et al. Effect of bipolar disorder on lymphocyte inositol monophosphatase mRNA levels. Int. J.Neuropsychopharmacol. 1999;2:25–29. https://doi.org/10.1017/s1461145799001315
  15. Yoon IS et al. Altered IMPA2 gene expression and calcium homeostasis in bipolar disorder. Mol. Psychiatry 2001;6:678–683. https://doi.org/10.1038/sj.mp.4000901
  16. Shamir A et al. Inositol monophosphatase in immortalized lymphoblastoid cell lines indicates susceptibility to bipolar disorder and response to lithium therapy. Mol. Psychiatry 1998;3:481–482. https://doi.org/10.1038/sj.mp.4000470
  17. Friedman E et al. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol. Psychiatry 1993;33:520–525. https://doi.org/10.1016/0006-3223(93)90006-y
  18. Wang HY et al. Increased membrane-associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients. J. Psychiatr. Res. 1999;33:171–179. https://doi.org/10.1016/s0022-3956(98)90057-7
  19. Hahn CG et al. Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. J. Psychiatr. Res. 2005;39:355–363. https://doi.org/10.1016/j.jpsychires.2004.10.007
  20. Klein PS, Melton, DA. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U. S. A. 1996;93:8455–8459. https://doi.org/10.1073/pnas.93.16.8455
  21. Chen G et al. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 1999;72:1327–1330. https://doi.org/10.1046/j.1471-4159.2000.0721327.x
  22. Yin L et al. Nuclear receptor Rev-erba is a critical lithium sensitive component of the circadian clock. Science 2006;311:1002–1005. https://doi.org/10.1126/science.1121613
  23. Kato T et al. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J. Affect. Disord. 1994;31:125–133. https://doi.org/10.1016/0165-0327(94)90116-3
  24. Kato T et al. Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. J. Affect. Disord. 1993;27:53–59. https://doi.org/10.1016/0165-0327(93)90097-4
  25. Dager SR et al. Brain metabolic alterations in medication free patients with bipolar disorder. Arch. Gen. Psychiatry 2004;61:450–458. 
  26. Hamakawa H et al. Quantitative proton magnetic resonance spectroscopy of the bilateral frontal lobes in patients with bipolar disorder. Psychol. Med. 1999;29:639–644. https://doi.org/10.1017/s0033291799008442
  27. Port JD et al. Metabolic alterations in medication-free patients with bipolar disorder: a 3T CSF- corrected magnetic resonance spectroscopic imaging study. Psychiatry Res. 2008;162:113–121. https://doi.org/10.1016/j.pscychresns.2007.08.004
  28. Frey BN et al. Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication free individuals with bipolar disorder: an in vivo 1H MRS study. Bipolar Disord. 2007;9 (Suppl. 1):119–127. https://doi.org/10.1111/j.1399-5618.2007.00454.x
  29. Suomalainen A et al. Multiple deletions of mitochondrial DNA in several tissues of a patient with severe retarded depression and familial progressive external ophthalmoplegia. J. Clin. Invest. 1992;90:61–66. https://doi.org/10.1172/jci115856
  30. Siciliano G et al. Autosomal dominant external ophthalmoplegia and bipolar affective disorder associated with a mutation in the ANT1 gene. Neuromuscul.Disord. 2003;13:162–165. https://doi.org/10.1016/s0960-8966(02)00221-3
  31. Fattal O et al. Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr. 2007;12:429–438. https://doi.org/10.1017/s1092852900015303
  32. Kato T, Kato, N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2000;2:180–190. https://doi.org/10.1034/j.1399-5618.2000.020305.x
  33. Kato T et al. Increased levels of a mitochondrial DNA deletion in the brain of patients with bipolar disorder. Biol. Psychiatry 1997;42:871–875. https://doi.org/10.1016/s0006-3223(97)00012-7
  34. Konradi C et al. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch. Gen. Psychiatry 2004;61:300–308.            
  35. Naydenov AV et al. Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress. Arch. Gen. Psychiatry 2007;64:555–564. https://doi.org/10.1001/archpsyc.64.5.555
  36. Van Goethem G et al. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat. Genet. 2001;28:211–212. https://doi.org/10.1038/90034
  37. Kasahara T et al. Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes. Mol. Psychiatry 2006;11:577–593. https://doi.org/10.1038/sj.mp.4001824
  38. Kasahara T et al. A marked effect of electroconvulsive stimulation on behavioral aberration of mice with neuron-specific mitochondrial DNA defects. PLoS ONE 2008;3:e1877. https://doi.org/10.1371/journal.pone.0001877
  39. Kubota M et al. Abnormal Ca2+ dynamics in transgenic mice with neuron-specific mitochondrial DNA defects. J. Neurosci. 2006;26:12314–12324. https://doi.org/10.1523/jneurosci.3933-06.2006
  40. Andreazza AC et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J. Affect. Disord.    
  41. Reimold AM et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001;412:300–307.                
  42. So J et al. Impaired endoplasmic reticulum stress response in B-lymphoblasts from patients with bipolar-I disorder. Biol. Psychiatry 2007;62:141–147. https://doi.org/10.1016/j.biopsych.2006.10.014
  43. Hayashi A et al. The role of brain-derived neurotrophic factor (BDNF)-induced XBP1 splicing during brain development. J. Biol.Chem. 2007;282:34525–34534. https://doi.org/10.1074/jbc.m704300200
  44. Hayashi A et al. Attenuated BDNF-induced upregulation of GABAergic markers in neurons lacking Xbp1. Biochem Biophys Res Commun. 2008;376:758-63. https://doi.org/10.1016/j.bbrc.2008.09.059
  45. Shim J et al. The unfolded protein response regulates glutamate receptor export from the endoplasmic reticulum. Mol.Biol. Cell 2004;15:4818–4828. https://doi.org/10.1091/mbc.e04-02-0108
  46. Kuratomi G et al. Aberrant DNA methylation associated with bipolar disorder identified from discordant monozygotic twins. Mol.Psychiatry 2008;13:429–441. https://doi.org/10.1038/sj.mp.4002001
  47. Videbech P. MRI findings in patients with affective disorder: a meta-analysis. Acta Psychiatr. Scand. 1997;96:157–168. https://doi.org/10.1111/j.1600-0447.1997.tb10146.x
  48. Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol. Bull. 2001;35:5–49. https://doi.org/10.64719/pb.4260
  49. Benes FM et al. The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol. Psychiatry 2001;50:395–406. https://doi.org/10.1016/s0006-3223(01)01084-8
  50. Bouras C et al. Anterior cingulate cortex pathology in schizophrenia and bipolar disorder. Acta Neuropathol. 2001;102:373–379. https://doi.org/10.1007/s004010100392
  51. Cotter D et al. The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol. Psychiatry 2002;51:377–386. https://doi.org/10.1016/s0006-3223(01)01243-4
  52. Rajkowska G et al. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol. Psychiatry 2001;49:741–752. https://doi.org/10.1016/s0006-3223(01)01080-0
  53. Beasley CL et al. Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol. Psychiatry 2002;52:708–715. https://doi.org/10.1016/s0006-3223(02)01360-4
  54. Benes FM et al. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol. Psychiatry 1998;44:88–97. https://doi.org/10.1016/s0006-3223(98)00138-3
  55. Kromkamp M et al. Decreased thalamic expression of the homeobox gene DLX1 in psychosis. Arch. Gen. Psychiatry 2003;60:869–874. https://doi.org/10.1001/archpsyc.60.9.869
  56. Manaye KF et al. Selective neuron loss in the paraventricular nucleus of hypothalamus in patients suffering from major depression and bipolar disorder. J. Neuropathol. Exp. Neurol. 2005;64: 224–229. https://doi.org/10.1093/jnen/64.3.224
  57. Nonaka S et al. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc. Natl. Acad. Sci. U. S. A. 1998;95:2642–2647. https://doi.org/10.1073/pnas.95.5.2642
  58. Chen G et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 1999;72:879–882. https://doi.org/10.1046/j.1471-4159.1999.720879.x
  59. Williams RS et al. A common mechanism of action for three mood-stabilizing drugs. Nature 2002;417:292–295.
  60. Chen G et al. Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 2000;75: 1729–1734.         
  61. Hao Y et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci. 2004;24:6590–6599. https://doi.org/10.1523/jneurosci.5747-03.2004
  62. Laeng P et al. The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells. J. Neurochem. 2004;91:238–251. https://doi.org/10.1111/j.1471-4159.2004.02725.x
  63. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U. S. A. 1996;93:8455–8459. https://doi.org/10.1073/pnas.93.16.8455
  64. Chen G et al. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 1999;72:1327–1330. https://doi.org/10.1046/j.1471-4159.2000.0721327.x
  65. Du J et al. Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression. Ann. N. Y. Acad. Sci. 2003;1003:378–380. https://doi.org/10.1196/annals.1300.031
  66. Zhou R et al. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J. Neurosci. 2005;25:4493–4502. https://doi.org/10.1523/jneurosci.4530-04.2005
  67. Basta-Kaim A et al. Mood stabilizers inhibit glucocorticoid receptor function in LMCAT cells. Eur. J. Pharmacol. 2004;495:103–110. https://doi.org/10.1016/j.ejphar.2004.05.034
  68. Cui J et al. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 2007;144:1447–1453. https://doi.org/10.1016/j.neuroscience.2006.11.010
  69. Higashi M et al. Mood stabilizing drugs expand the neural stem cell pool in the adult brain through activation of notch signaling. Stem Cells 2008;26:1758–1767. https://doi.org/10.1634/stemcells.2007-1032
  70. Leng Y et al. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J. Neurosci. 2008;28:2576–2588. https://doi.org/10.1523/jneurosci.5467-07.2008
  71. Brennan BP et al. Rapid Enhancement of Glutamatergic Neurotransmission in Bipolar Depression Following Treatment with Riluzole. Neuropsychopharmacology 2010;35:834-846. https://doi.org/10.1038/npp.2009.191
  72. Post RM, Weiss SR. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Mol. Neurobiol. 1996;13:33–60. https://doi.org/10.1007/bf02740751
  73. Levinson AJ et al. Cortical inhibitory dysfunction in bipolar disorder: a study using transcranial magnetic stimulation. J. Clin. Psychopharmacol. 2007;27:493–497. https://doi.org/10.1097/jcp.0b013e31814ce524
  74. Benes FM et al. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol. Psychiatry 1998;44:88–97. https://doi.org/10.1016/s0006-3223(98)00138-3
  75. Benes FM et al. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc. Natl. Acad. Sci. U.S. A. 2007;104:10164–10169. https://doi.org/10.1073/pnas.0703806104
  76. Lewy AJ et al. Manic-depressive patients may be supersensitive to light. Lancet 1981;1:383–384. https://doi.org/10.1016/s0140-6736(81)91697-4
  77. Frank E et al. Interpersonal and social rhythm therapy: an intervention addressing rhythm dysregulation in bipolar disorder. Dialogues Clin.Neurosci. 2007;9:325–332. https://doi.org/10.31887/dcns.2007.9.3/efrank